Get the Stockscreener App
3.28
1.13%
0.05
Pds Biotechnology Corporation stock is traded at $3.28, with a volume of 255.10K.
It is up +1.13% in the last 24 hours and down -11.95% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
See More
Previous Close:
$3.23
Open:
$3.21
24h Volume:
255.10K
Relative Volume:
0.87
Market Cap:
$118.93M
Revenue:
-
Net Income/Loss:
$-42.94M
P/E Ratio:
-2.0247
EPS:
-1.62
Net Cash Flow:
$-33.64M
1W Performance:
+1.44%
1M Performance:
-11.95%
6M Performance:
-14.49%
1Y Performance:
-28.21%
1-Day Range:
$3.15
$3.32
1-Week Range:
$3.07
$3.44
52-Week Range:
$2.53
$6.85
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Name
Pds Biotechnology Corporation
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corporation Stock (PDSB) Latest News
Contrasting Semiconductor Manufacturing International (OTCMKTS:SMICY) & POET Technologies (NASDAQ:POET) - Defense World
StockNews.com Initiates Coverage on Ark Restaurants (NASDAQ:ARKR) - Defense World
Jones Soda Announces Departure of President and CEO, David Knight, and Appointment of Interim CEO, Paul Norman - Defense World
Mastech Digital (NYSE:MHH) Coverage Initiated by Analysts at StockNews.com - Defense World
Head-To-Head Analysis: Edison International (NYSE:EIX) and AltC Acquisition (NYSE:ALCC) - Defense World
FS KKR Capital Corp. (NYSE:FSK) Given Consensus Rating of “Hold” by Brokerages - Defense World
StockNews.com Begins Coverage on TRX Gold (NYSE:TRX) - Defense World
Mastech Digital (NYSE:MHH) Now Covered by Analysts at StockNews.com - Defense World
PDS Biotechnology Co. (NASDAQ:PDSB) Receives $14.25 Consensus Price Target from Analysts - MarketBeat
Oaktree Specialty Lending Co. (NASDAQ:OCSL) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Zacks Research Issues Negative Estimate for CSX Earnings - Defense World
Hillman Solutions (HLMN) to Announce Quarterly Earnings on Tuesday - Defense World
Evolv Technology Holdings CEO terminated, replaced by Michael Ellenbogen as Interim CEO - Defense World
Chase (NYSE:CCF) Now Covered by Analysts at StockNews.com - Defense World
PDS Biotechnology (NASDAQ:PDSB) Stock Rating Upgraded by StockNews.com - MarketBeat
HC Wainwright Reaffirms Buy Rating for PDS Biotechnology (NASDAQ:PDSB) - MarketBeat
Is There More Room To Run For This Immunotherapy Company Stock After Hitting New High? - RTTNews
PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine - The Manila Times
NY Biopharma Shares Promising Clinical Data - Streetwise Reports
Data Readouts At ASCO (MRUS, ORIC, CGEN, PDSB...) - RTTNews
H.C. Wainwright & Co. Shares Buy Rating on Biotech Co. - Streetwise Reports
PDS Biotechnology Co. (NASDAQ:PDSB) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market Size, Spotlight on Future Potentials (2024-2034) - IndiaPolitics.com
CD47 Inhibitors Market Projected to Grow Significantly with Emerging Cancer Therapies by 2034 | DelveInsight - The Malaysian Reserve
Mass. Biotech Receives FDA Approval - Streetwise Reports
PDS Biotechnology Corporation: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
PDS Biotechnology Corporation (PDSB)’s stock price range in the last year - US Post News
Capsule Filler Machine Industry to Eyewitness Massive Growth - Elektrotransports.lv
Major Improvements In Hershey Company (HSY) Stock Need To Be Considered - Stocks Register
Biotech Alert: Searches spiking for these stocks today - TipRanks
PDS Biotechnology shares maintain Buy rating from H.C. Wainwright on positive trial results By Investing.com - Investing.com South Africa
PDS Biotechnology shares maintain Buy rating from H.C. Wainwright on positive trial results - Investing.com India
Biotech Completes Last Patient Visit in Phase2b Osteosarcoma Trial - Streetwise Reports
Investor’s Delight: PDS Biotechnology Corporation (PDSB) Closes Strong at 4.11, Up 12.60 - The Dwinnex
XTX Topco Ltd Invests $57,000 in 3D Systems Co. (NYSE:DDD) - Defense World
Locally Advanced Cervical Cancer Phase 2 Study Publishes Positive Results - Precision Vaccinations
PDS Biotech reports promising phase 2 cervical cancer trial results By Investing.com - Investing.com Canada
PDS Biotech reports promising phase 2 cervical cancer trial results - Investing.com
New Jersey Biotech Reports Positive Survival Data - Streetwise Reports
This trade activity should not be overlooked: PDS Biotechnology Corporation (PDSB) - SETE News
PDS Biotechnology (NASDAQ:PDSB) Given "Buy" Rating at HC Wainwright - MarketBeat
PDS Biotechnology’s Versamune® HPV Shows Promise in Phase 2 Trial - TipRanks
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation - The Manila Times
PDSB’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
A venture capital company on a huge discount - Investors Chronicle
PDSB’s current quarter earnings: What analysts forecast? - US Post News
Three North Jersey startup tech firms get aid through state program - NorthJersey.com
Three North Jersey startup tech firms get state financing for R&D and salaries - Daily Record
What's Going On With Vistra Stock? - MSN
PDS Biotechnology: Continuing The Holding Pattern (NASDAQ:PDSB) - Seeking Alpha
Pds Biotechnology Corporation Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):